FIELD: medicine.
SUBSTANCE: (R)-7-chlor-N-(quinuclidin-3-yl)benzo[b]thiophen-2-carboxamide is administered in a daily dose of 0.1-3.0 mg.
EFFECT: providing the procognitive effect in the patients suffering from Alzheimer disease or schizophrenia with minimum side effects.
9 cl, 3 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF COGNITIVE DISORDERS WITH (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | 2014 |
|
RU2662560C2 |
| METHODS FOR COGNITIVE FUNCTION SUPPORT, TREATMENT OR IMPROVEMENT | 2013 |
|
RU2635522C2 |
| CRYSTALLINE FORM OF (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO[b]THIOPHENE-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE | 2011 |
|
RU2577334C2 |
| HETEROAROMATIC NMDA RECEPTOR MODULATORS AND THEIR USE | 2019 |
|
RU2800064C2 |
| INDAZOLES, BENTOTHIAZOLES, BENZOISOTHIAZOLES, PRODUCTION AND USE THEREOF | 2003 |
|
RU2391341C2 |
| ALKALOID DERIVATIVES OF AMINOESTERS AND THEREOF-INCLUDING DRUG COMPOSITIONS | 2011 |
|
RU2569846C2 |
| METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA WITH USING NEUROLEPTIC COMBINED THERAPY | 2007 |
|
RU2508096C2 |
| BENZO[d] ISOXAZOLE-3 DAAO INHIBITORS | 2004 |
|
RU2384574C2 |
| METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA WITH USING ATYPICAL NEUROLEPTIC COMBINED THERAPY | 2007 |
|
RU2508106C2 |
| SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-a]PYRIMIDINE-2,6-DIAMINES, SEROTONIN 5-HT RECEPTOR ANTAGONISTS, METHODS OF PRODUCING AND USING SAID COMPOUNDS | 2010 |
|
RU2421456C1 |
